ArticleCell reports2020

Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress.

Michael D Nyquist et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.